Terms: = Head and neck cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Clinical Outcome
24 results:
1. Prognostic biomarkers for survival in mucosal melanoma.
Thierauf JC; Kaluziak ST; Codd E; Dybel SN; Jobbagy S; Purohit R; Farahani AA; Dedeilia A; Naranbhai V; Hoang MP; Fisch AS; Ritterhouse L; Boland GM; Lennerz JK; Iafrate AJ
Pigment Cell Melanoma Res; 2023 Sep; 36(5):378-387. PubMed ID: 37390098
[TBL] [Abstract] [Full Text] [Related]
2. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract] [Full Text] [Related]
3. Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiring.
Chaudhary S; Pothuraju R; Rachagani S; Siddiqui JA; Atri P; Mallya K; Nasser MW; Sayed Z; Lyden ER; Smith L; Gupta SD; Ralhan R; Lakshmanan I; Jones DT; Ganti AK; Macha MA; Batra SK
Cancer Lett; 2021 Jul; 510():79-92. PubMed ID: 33878394
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive functional genomic analyses link APC somatic mutation and mRNA-miRNA networks to the clinical outcome of stage-III colorectal cancer patients.
Chiang SF; Huang HH; Tsai WS; Chin-Ming Tan B; Yang CY; Huang PJ; Yi-Feng Chang I; Lin J; Lu PS; Chin E; Liu YH; Yu JS; Chiang JM; Hung HY; You JF; Liu H
Biomed J; 2022 Apr; 45(2):347-360. PubMed ID: 35550340
[TBL] [Abstract] [Full Text] [Related]
5. Significance of druggable targets (PD-L1, kras, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
[TBL] [Abstract] [Full Text] [Related]
6. Autophagic reliance promotes metabolic reprogramming in oncogenic kras-driven tumorigenesis.
Lin HH; Chung Y; Cheng CT; Ouyang C; Fu Y; Kuo CY; Chi KK; Sadeghi M; Chu P; Kung HJ; Li CF; Limesand KH; Ann DK
Autophagy; 2018; 14(9):1481-1498. PubMed ID: 29956571
[TBL] [Abstract] [Full Text] [Related]
7. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.
Salem ME; Puccini A; Xiu J; Raghavan D; Lenz HJ; Korn WM; Shields AF; Philip PA; Marshall JL; Goldberg RM
Oncologist; 2018 Nov; 23(11):1319-1327. PubMed ID: 29866946
[TBL] [Abstract] [Full Text] [Related]
8. Thy-1
Schliekelman MJ; Creighton CJ; Baird BN; Chen Y; Banerjee P; Bota-Rabassedas N; Ahn YH; Roybal JD; Chen F; Zhang Y; Mishra DK; Kim MP; Liu X; Mino B; Villalobos P; Rodriguez-Canales J; Behrens C; Wistuba II; Hanash SM; Kurie JM
Sci Rep; 2017 Jul; 7(1):6478. PubMed ID: 28744021
[TBL] [Abstract] [Full Text] [Related]
9. Mutually exclusive recurrent kras and MAP2K1 mutations in Rosai-Dorfman disease.
Garces S; Medeiros LJ; Patel KP; Li S; Pina-Oviedo S; Li J; Garces JC; Khoury JD; Yin CC
Mod Pathol; 2017 Oct; 30(10):1367-1377. PubMed ID: 28664935
[TBL] [Abstract] [Full Text] [Related]
10. PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and kras during Lung Tumorigenesis.
Zhou X; Updegraff BL; Guo Y; Peyton M; Girard L; Larsen JE; Xie XJ; Zhou Y; Hwang TH; Xie Y; Rodriguez-Canales J; Villalobos P; Behrens C; Wistuba II; Minna JD; O'Donnell KA
Cancer Res; 2017 Jan; 77(1):187-197. PubMed ID: 27821484
[TBL] [Abstract] [Full Text] [Related]
11. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
Kadara H; Choi M; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Yoo Y; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Wistuba II; Herbst RS
Ann Oncol; 2017 Jan; 28(1):75-82. PubMed ID: 27687306
[TBL] [Abstract] [Full Text] [Related]
12. The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma.
Skalova A; Sar A; Laco J; Metelkova A; Miesbauerova M; Steiner P; Švajdler M; Michal M
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):140-146. PubMed ID: 27258560
[TBL] [Abstract] [Full Text] [Related]
13. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
[TBL] [Abstract] [Full Text] [Related]
14. Molecular Characteristics of Basaloid Squamous Cell Carcinoma of the Esophagus: Analysis of kras, BRAF, and PIK3CA Mutations and LINE-1 Methylation.
Baba Y; Ishimoto T; Harada K; Kosumi K; Murata A; Miyake K; Hiyoshi Y; Kurashige J; Iwatsuki M; Iwagami S; Miyamoto Y; Sakamoto Y; Yoshida N; Oki E; Iyama K; Watanabe M; Baba H
Ann Surg Oncol; 2015 Oct; 22(11):3659-65. PubMed ID: 25691283
[TBL] [Abstract] [Full Text] [Related]
15. Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.
Schechter RB; Nagilla M; Joseph L; Reddy P; Khattri A; Watson S; Locati LD; Licitra L; Greco A; Pelosi G; Carcangiu ML; Lingen MW; Seiwert TY; Cohen EE
Cancer Lett; 2015 Apr; 359(2):269-74. PubMed ID: 25641339
[TBL] [Abstract] [Full Text] [Related]
16. The degree of segmental aneuploidy measured by total copy number abnormalities predicts survival and recurrence in superficial gastroesophageal adenocarcinoma.
Davison JM; Yee M; Krill-Burger JM; Lyons-Weiler MA; Kelly LA; Sciulli CM; Nason KS; Luketich JD; Michalopoulos GK; LaFramboise WA
PLoS One; 2014; 9(1):e79079. PubMed ID: 24454681
[TBL] [Abstract] [Full Text] [Related]
17. Is biomarker research advancing in the era of personalized medicine for head and neck cancer?
Yokota T
Int J Clin Oncol; 2014 Apr; 19(2):211-9. PubMed ID: 24442754
[TBL] [Abstract] [Full Text] [Related]
18. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and kras/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.
Bettstetter M; Berezowska S; Keller G; Walch A; Feuchtinger A; Slotta-Huspenina J; Feith M; Drecoll E; Höfler H; Langer R
Hum Pathol; 2013 May; 44(5):829-36. PubMed ID: 23158210
[TBL] [Abstract] [Full Text] [Related]
19. Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas.
Smilek P; Neuwirthova J; Jarkovsky J; Dusek L; Rottenberg J; Kostrica R; Srovnal J; Hajduch M; Drabek J; Klozar J
Neoplasma; 2012; 59(5):508-15. PubMed ID: 22668015
[TBL] [Abstract] [Full Text] [Related]
20. Human papillomavirus and gene mutations in head and neck squamous carcinomas.
Friedland P; Thomas A; Naran A; Amanuel B; Grieu-Iacopetta F; Carrello A; Harnett G; Meyer C; Phillips M
ANZ J Surg; 2012 May; 82(5):362-6. PubMed ID: 22507644
[TBL] [Abstract] [Full Text] [Related]
[Next]
